BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Vitiligo clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for vitiligo: 39 (28 sponsors; 14 newly posted in the last 180 days, 1 stopped in the last 180 days; 9 new-entrant sponsors). Momentum score 35.9, rank 2 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 0, Phase 1 5, Phase 2 16, Phase 3 14, Phase 4 0, N/A 4.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
Incyte Corporation INCY4P3 401
AbbVie ABBV3NA 1, P3 210
Pfizer PFE2P3 201
Teva Branded Pharmaceutical Products R&D LLC2P1 1, P3 110
Beijing InnoCare Pharma Tech Co., Ltd.1P3 100
Clinuvel, Inc. CUVL1P3 100
Dermavon Holdings Limited new entrant1P3 110
Minghui Pharmaceutical (Hangzhou) Ltd new entrant1P3 110
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. new entrant1P3 110
Genrix (Shanghai) Biopharmaceutical Co., Ltd. new entrant2P2 220
Jiangsu HengRui Medicine Co., Ltd.2P2 201
Jiangsu vcare pharmaceutical technology co., LTD2P2 210
Target PharmaSolutions, Inc. TGT2NA 210
CAGE Bio Inc.1P1 101
Dren Bio1P1 101
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. new entrant1P2 111
Edesa Biotech Inc. EDSA new entrant1P2 110
Eli Lilly and Company LLY1P2 101
Elixiron Immunotherapeutics (Hong Kong) Ltd.1P2 101
Forte Biosciences, Inc.1P1 101
Hudson Biotech1P2 101
Idorsia Pharmaceuticals Ltd. new entrant1P2 110
Innovent Biologics (Suzhou) Co. Ltd.1P1 100
InventisBio Co., Ltd new entrant1P2 110
Novartis Pharmaceuticals NVS1P2 100

New-entrant sponsors: Dermavon Holdings Limited, Minghui Pharmaceutical (Hangzhou) Ltd, Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd., Genrix (Shanghai) Biopharmaceutical Co., Ltd., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Edesa Biotech Inc., Idorsia Pharmaceuticals Ltd., InventisBio Co., Ltd.

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-31 est.P2Elixiron Immunotherapeutics (Hong Kong) Ltd.NCT07223229 Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo PatientsNon-segmental Vitiligorecruiting45
2026-12-31 est.P2E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.NCT07712523 A Multicenter, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of QY201 Tablets in SubjAdult Subjects With Non-Segmental Vitiligorecruiting200
2027-02-14 est.P2Hudson BiotechNCT07437560 Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental VitiligoNonSegmental Vitiligo; Nonsegmental Vitiligo (Stable)recruiting60

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
None found.

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "vitiligo"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.